F0

Fortive CorpDUS Fortive Stock Report

Last reporting period 27 Sep, 2024

Updated 21 Nov, 2024

Last price

Market cap $B

27.071

Large

Exchange

XDUS - Boerse Duesseldorf

F03.DU Stock Analysis

F0

Neutral

Based on Eyestock quantitative analysis, F03.DU`s fundamental data and valuation indicate an investment grade of Neutral at the current time.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

65/100

Moderate score

Upside

To determine whether the current price is a reasonable to buy a stock, we compare it to our estimate of fair value. The more undervalued a stock is, the higher the upside.

4.4 %

Undervalued

Market cap $B

27.071

Dividend yield

0.44 %

Shares outstanding

353.2 B

Fortive Corp. engages in the design, development, manufacturing, and marketing of professional and engineered products, software, and services for a variety of end markets. The company is headquartered in Everett, Washington and currently employs 18,000 full-time employees. The company went IPO on 2016-06-13. The company operates through three segments: Intelligent Operating Solutions, Precision Technologies, and Advanced Healthcare Solutions. Intelligent Operating Solutions segment offers various Products and services under a range of brands, including Accruent, Fluke, Gordian, Industrial Scientific, Intelex, Pruftechnik, and Servicechannel. Precision Technologies segment provides electrical test and measurement instruments and services, energetic material devices, and a range of sensor and control system solutions. Advanced Healthcare Solutions segment provides hardware, consumables, software and services that helps in the customers' workflows, including instrument sterilization and device reprocessing, instrument tracking, cell therapy equipment design and manufacturing, biomedical test tools, radiation safety monitoring, end-to-end clinical productivity solutions and asset

View Section: Eyestock Rating